±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2026ÄêÑо¿ÉúÕÐÉú½ÓÊÕµ÷¼Á¹«¸æ
²é¿´: 2301  |  »Ø¸´: 12
µ±Ç°Ö÷ÌâÒѾ­´æµµ¡£
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

yalefield

½ð³æ (ÎÄ̳¾«Ó¢)

ÀϺºÒ»Ã¶

[½»Á÷] ÏÈÉùÒ©ÒµµÄ¶÷¶È£¨ENDOSTAR£©[ת]

×÷ÕߣºJingyi

¡¡¡¡2007Äê³õ£¬ÖйúµÄÒ»¼ÒÖÆÒ©¹«Ë¾ÏÈÉùÖÆÒ©ÔÚŦԼÉÏÊС£ÆäÖ÷Òª²úÆ·ÊÇ¡°¶÷¶È¡±(ENDOSTAR)£¬Ò»ÖÖÒÖÖÆÑª¹ÜÉú³¤µÄÒ©ÎÖ÷ÒªÕë¶Ô·ÇСϸ°û·Î°©(NSCLC)¡£ÕâÊÇÒ»Öַdz£ÆÕ±éµÄ¶ñÐÔÖ×Áö£¬¾­³£ÓÉÎüÑÌÓÕ·¢¡£

¡¡¡¡¼ÇµÃÒÔǰ¿´¹ýһЩÎÄÕ£¬½éÉÜͨ¹ýÒÖÖÆÑª¹ÜÉú³¤¡°¶öËÀ¡±°©Ï¸°û¡£Ã»Ïëµ½ÏÖÔÚÒѾ­³ö²úÆ·£¬¶øÇÒÊÇÕë¶ÔÖйú·Ç³£ÆÕ±éµÄ·Î°©¡£¿Éϲ¿ÉºØ¡£

¡¡¡¡µ«ÊÇ×ÐϸÑо¿Ò»Ï£¬È´·¢ÏÖÎÊÌâ¡£

    ¶÷¶ÈµÄÖ÷Òª³É·Ö(Endostatin)ÔÚ¹úÍâµÄ¶þÆÚÁÙ´²Öб»Åж¨Ã»ÓÐÃ÷ÏÔЧ¹û¡£(Note 1) µ±³õÑо¿¸ÃÒ©µÄÒ»¼ÒÃÀ¹úÉú»¯¹«Ë¾EntreMed¼¸ºõÆÆ²ú¡£²Æ¸»ÔÓÖ¾ÆÀÂÛ˵£¬¸ÃÒ©¡°Ï·¾çÐÔµÄʧ°ÜÁË¡±¡£(Note 2)
    µ«ÊÇ£¬¸Ã¹«Ë¾ÔÚÖйú×öµÄ493ÀýÈ´·¢ÏÖʹÓö÷¶È¿ÉÒÔʹ1ÄêÉú´æÂÊ´Ó31%Ôö¼Óµ½63%£¬Æ½¾ùÉú´æÊÙÃüÊǶÔÕÕ×éµÄ5±¶¡£(Note 3£©¡£

¡¡¡¡ÏÖÔÚ¶÷¶ÈÒѾ­ÔÚÖйú500¶à¼ÒҽԺʹÓã¬ÓÃÓÚÖÎÁÆÖйú´óÁ¿ÒòÎüÑ̶øµÃ·Î°©µÄ²¡ÈË¡£ºÜÆæ¹ÖΪʲô¹úÄÚÍâµÄÁÙ´²½á¹û²îÒìÕâô´ó¡£ÓÐûÓÐÄÄλרҵÈËÊ¿Ñо¿Ò»Ï¡£

Note:
1. Kulke M H et al (2006). "Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors". J. Clin. Oncol. 24: 3555-3561.
2. http://yalemedicine.yale.edu/ym_sp06/booksideas.html
3. Company Prospectus - Strong Growth Potential of Our Innovative Pharmaceutical Endu
»Ø¸´´ËÂ¥

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

WANTTOKNOW

Òø³æ (ÖøÃûдÊÖ)

¶ÔÓÚ°©Ö¢£¬¼ÙÒ©ÕæÒ©¶¼Êǻƽð¼Û£»

½á¹ûÊÇ»¼ÕßÈ˲ÆÁ½¿Õ¡£
7Â¥2008-01-17 17:16:52
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 13 ¸ö»Ø´ð

wangw2008

½ð³æ (Ö°Òµ×÷¼Ò)

´¿½àÔÚ¼ËÔº,¶éÂäÔÚ½ÌÓý²¿.

±¾ÈËÒ²Ò»Ö±ÔÚ»³ÒÉÕâ¸öÊý¾Ý£¬ÏÈÉùµÄËÄÆÚÁÙ´²Êý¾Ý×öµÄºÜ²î£¬ÖÁÓÚ£±£¬£²ÆÚµÄÊý¾ÝÔõôÀ´µÄ£®´ó¸ÅÖ»ÓÐÖйúµÄÕâ¸ö»·¾³Ï²Żá³öÏÖ£®
ÑÏÕýÉùÃ÷: ±¾ÌûÄÚÈÝÎ´Éæ¼°¹¥»÷ÈκγæÓÑ(°üÀ¨ÒÔָɣÂî»±£¬º¬É³ÉäÓ°µÈÐÎʽ),²»Ó°ÏìºÈѪ(ɽ¶«»°ºÍг)
2Â¥2007-12-19 07:07:49
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

¶¹¸ç

Ö÷¹ÜÇø³¤ (Ö°Òµ×÷¼Ò)

ÖÆÁ£ÄÜÊÖ

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

ÕâÑùµÄ»°Ò©ÎïûÓÐÁÆÐ§ÔõôÄÜÒ»Ö±ÔÚÁÙ´²ÉÏÓÃÄØ£¿
±ßѧ±ßÎÊ£¬²ÅÓÐѧÎÊ¡£
3Â¥2007-12-19 14:00:23
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
4Â¥2007-12-19 14:13:57
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ¿¼Ñе÷¼ÁÉúѰÕÒµ¼Ê¦ +3 ¹ËÕ°¿¼Ñа¡ 2026-04-05 3/150 2026-04-05 18:18 by à£à£à£0119
[¿¼ÑÐ] ±¾¿Æ211ÉúÎïҽѧ¹¤³Ì085409Çóµ÷¼Á339·Ö +9 Àï×Óľyy 2026-03-29 9/450 2026-04-05 17:38 by Ecowxq666£¡
[¿¼ÑÐ] ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£© +8 ÏàÐűػá¹ââÍòÕ 2026-04-05 10/500 2026-04-05 12:19 by Hdyxbekcb
[¿¼ÑÐ] Çóµ÷¼Á +3 µçÆøÐ¡Éñͯ 2026-04-04 3/150 2026-04-05 10:17 by barlinike
[¿¼ÑÐ] 085602µ÷¼Á ³õÊÔ×Ü·Ö335 +12 19123253302 2026-04-04 12/600 2026-04-05 08:08 by 544594351
[¿¼²©] É격 +7 IQwQl 2026-04-04 7/350 2026-04-04 23:32 by mumin1990
[¿¼ÑÐ] ²ÄÁϵ÷¼Á +18 Ò»ÑùYWY 2026-04-02 19/950 2026-04-04 22:14 by hemengdong
[¿¼ÑÐ] 333Çóµ÷¼Á +12 wfh030413@ 2026-04-03 13/650 2026-04-04 21:02 by jj987
[¿¼ÑÐ] 085602 ÕÒµ÷¼Á +4 ÄæÊ±Õë¿ìÀÖ 2026-04-02 4/200 2026-04-04 19:32 by À¶ÔÆË¼Óê
[¿¼ÑÐ] 348·Ö»·¾³¹¤³Ì¡¤µ÷¼Á +10 ÎâÑå׿24k 2026-04-03 11/550 2026-04-04 14:19 by Î޼ʵIJÝÔ­
[¿¼ÑÐ] ¿¼Ñе÷¼Á +3 15615482637 2026-04-03 3/150 2026-04-03 22:50 by ms629
[¿¼ÑÐ] 322Çóµ÷¼Á +6 FZAC123 2026-04-03 6/300 2026-04-03 22:23 by ¿ÆÑÐСר¼Ò
[¿¼ÑÐ] 288Çóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó ²ÄÁÏÓ뻯¹¤ +39 ÂåÉñ¸ç¸ç 2026-03-31 41/2050 2026-04-03 21:51 by qlm5820
[¿¼ÑÐ] ѧ˶288µ÷¼Á!!! +3 СÍõxw123 2026-04-03 3/150 2026-04-03 21:20 by à£à£à£0119
[¿¼ÑÐ] 273Çóµ÷¼Á +20 ÀîÜÆÐÂ1 2026-03-31 20/1000 2026-04-03 09:58 by linyelide
[¿¼ÑÐ] ÖØÇì´óѧ²ÄÁÏÓ뻯¹¤085600£¬³õÊÔ370+£¬ÇóÇóµ÷¼Á½¨Òé +8 shzhou_ 2026-04-01 9/450 2026-04-03 09:31 by À¶ÔÆË¼Óê
[¿¼ÑÐ] Ò»Ö¾Ô¸¸´µ©²ÄÁÏ£¬Ó¢Ò»×¨Ë¶£¬×Ü·Ö357µ÷¼Á +4 1050389037 2026-04-02 5/250 2026-04-02 21:40 by dongzh2009
[¿¼ÑÐ] Çóµ÷¼ÁÍÆ¼ö +3 ÄÏɽÄÏ@ 2026-04-01 3/150 2026-04-02 12:09 by xiaoranmu
[¿¼ÑÐ] 07ÉúÎïѧÇóµ÷¼Á һ־Ըͬ¼Ã´óѧ359·Ö +3 LAMC. 2026-03-30 3/150 2026-04-02 10:26 by 18828373951
[¿¼ÑÐ] 085404 22408 315·Ö +5 zhuangyan123 2026-03-31 6/300 2026-03-31 13:48 by limeifeng
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û